Results 41 to 50 of about 406,416 (358)

DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation [PDF]

open access: yes, 2016
Aberrant DNA methylation has been frequently observed in many human cancers, including rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children.
Camero, Simona   +11 more
core   +1 more source

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

open access: yesMolecular Cancer, 2007
Cyclin D1 is an important regulator of cell cycle progression and can function as a transcriptionl co-regulator. The overexpression of cyclin D1 has been linked to the development and progression of cancer. Deregulated cyclin D1 degradation appears to be
Alao John P
doaj   +1 more source

Cyclin K and cyclin D1b are oncogenic in myeloma cells

open access: yesMolecular Cancer, 2010
Background Aberrant expression of cyclin D1 is a common feature in multiple myeloma (MM) and always associated with mantle cell lymphoma (MCL). CCND1 gene is alternatively spliced to produce two cyclin D1 mRNA isoforms which are translated in two ...
Renoir Jack-Michel   +8 more
doaj   +1 more source

Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6 [PDF]

open access: yesStructure, 1999
Cyclin-dependent kinases (CDKs) have a central role in cell-cycle control and are activated by complex formation with positive regulatory proteins called cyclins and by phosphorylation. The overexpression and mutation of cyclins and CDKs has been associated with tumorigenesis and oncogenesis.
Schulze-Gahmen, Ursula   +2 more
openaire   +2 more sources

Cyclin E Expression and Proliferation in Breast Cancer

open access: yesAnalytical Cellular Pathology, 1998
Cyclin E is a part of the cell cycle machinery and aberrantly expressed in several malignancies including breast cancer. Since cyclin E is cell cycle specifically expressed, we wanted to examine the relation between proliferation and expression of cyclin
Niels H. Nielsen   +3 more
doaj   +1 more source

Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. [PDF]

open access: yesPLoS Biology, 2007
Activation of cyclin B1-cyclin-dependent kinase 1 (Cdk1), triggered by a positive feedback loop at the end of G2, is the key event that initiates mitotic entry.
Arne Lindqvist   +3 more
doaj   +1 more source

A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan [PDF]

open access: yes, 2008
A model describing the response of the growth of single human cells in the absence and presence of the anti-cancer agent topotecan (TPT) is presented. The model includes a novel coupling of both the kinetics of TPT and cell cycle responses to the agent ...
Ali, Reza   +7 more
core   +1 more source

Phosphorylation of cyclin O, a novel cyclin family protein containing a cyclin-like domain, is involved in the activation of cyclin-dependent kinase 2

open access: yesOncology Letters, 2014
Cell cycles, ordered series of events modulating cell growth and division, are tightly regulated by complexes containing cyclin-dependent kinases (CDKs) and cyclins. Cyclin O is a novel cyclin family protein which interacts with CDK2. However, the molecular effects of cyclin O on the activity of CDK2 have not been fully evaluated.
KIM, DO HYUNG   +5 more
openaire   +3 more sources

Immunohistochemical analysis of cyclin A expression in Wilms tumor [PDF]

open access: yesPeerJ, 2019
Background Cyclin A overexpression is found in a variety of human tumors and correlates with unfavorable outcome. We analyzed immunohistochemical expression of cyclin A in Wilms tumor (WT) in relation to clinicopathological characteristics, preoperative ...
Sanja Radojević-Škodrić   +9 more
doaj   +2 more sources

eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]

open access: yes, 2019
CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy